Received: 16 September 2020
Revised: 11 November 2020
Accepted: 12 November 2020
First Online: 8 January 2021
: Boston Children’s Hospital Institutional Review Board approved waiving consent for this study. Risks were determined to be minimal with no potential for direct benefit. Aetna gave approval for the manuscript submission, confirming that no beneficiaries were identifiable.
: S.F.M. is a Scientific Advisory Board member at Global Gene, Inc. Quest Diagnostics sponsors research for and contributes philanthropy for K.D.M.’s research program at Boston Children’s Hospital. The other authors declare no competing interests.